- Home
- NYC vs BOLD Comparison
NYC vs BOLD Comparison
Compare NYC & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYC
- BOLD
- Stock Information
- Founded
- NYC 2013
- BOLD 2018
- Country
- NYC United States
- BOLD United States
- Employees
- NYC N/A
- BOLD N/A
- Industry
- NYC Real Estate
- BOLD
- Sector
- NYC Finance
- BOLD
- Exchange
- NYC Nasdaq
- BOLD Nasdaq
- Market Cap
- NYC 28.8M
- BOLD 24.4M
- IPO Year
- NYC N/A
- BOLD 2024
- Fundamental
- Price
- NYC $10.35
- BOLD $1.13
- Analyst Decision
- NYC
- BOLD Buy
- Analyst Count
- NYC 0
- BOLD 4
- Target Price
- NYC N/A
- BOLD $4.00
- AVG Volume (30 Days)
- NYC 1.6K
- BOLD 75.0K
- Earning Date
- NYC 08-08-2025
- BOLD 08-05-2025
- Dividend Yield
- NYC N/A
- BOLD N/A
- EPS Growth
- NYC N/A
- BOLD N/A
- EPS
- NYC N/A
- BOLD N/A
- Revenue
- NYC $54,865,000.00
- BOLD N/A
- Revenue This Year
- NYC $8.40
- BOLD N/A
- Revenue Next Year
- NYC $1.62
- BOLD N/A
- P/E Ratio
- NYC N/A
- BOLD N/A
- Revenue Growth
- NYC N/A
- BOLD N/A
- 52 Week Low
- NYC $7.89
- BOLD $1.00
- 52 Week High
- NYC $16.30
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- NYC 36.47
- BOLD 46.56
- Support Level
- NYC $9.53
- BOLD $1.10
- Resistance Level
- NYC $10.96
- BOLD $1.16
- Average True Range (ATR)
- NYC 0.73
- BOLD 0.04
- MACD
- NYC -0.13
- BOLD -0.00
- Stochastic Oscillator
- NYC 23.63
- BOLD 40.00
About NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.